Clinical trials: sponsored by The Methodist Hospital Research Institute
Hepatocellular Carcinoma
Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients
This study will examine the effects of a six-month regimen of neoadjuvant lenvatinib in combination with transcatheter arterial chemoembolization (TACE) prior to liver transplantation in patients with hepatocellular carcinoma…
- Trial name
- NCT05171335
- Testing
- Lenvatinib, Transcatheter Arterial Chemoembolization
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- The Methodist Hospital Research Institute
Aortic Stenosis
Deep Learning Enhanced Detection of Aortic Stenosis - The DETECT-AS-Diagnostic Study
The DETECT-AS Diagnostic Study will assess the performance of artificial intelligence (AI) risk predictions to detect aortic stenosis using results from portable electrocardiogram (ECG) and cardiac ultrasound devices.
- Trial name
- NCT06749145
- Testing
- Portable 1-lead electrocardiogram, Point-of-care ultrasound, AI-ECG risk algorithm
- Where
- 3 sites in United States
- Volunteers
- 410 people, healthy volunteers welcome
- Sponsor
- Yale University
Lymphoma, Myeloma
Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL
Patients have a type of cancer called NHL, Multiple Myeloma (MM) or CLL that has come back or has not gone away after treatment.
- Conditions
- Lymphoma, Myeloma, Leukemia
- Trial name
- CHARKALL (NCT00881920)
- Testing
- Kappa CD28 T cells
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- Baylor College of Medicine
Multiple Myeloma
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
This study is for patients that have a cancer called Multiple Myeloma, monoclonal gammopathy of undetermined significance (MGUS) or smoldering myeloma (SM).
- Trial name
- TACTAM (NCT02291848)
- Testing
- TAA-specific CTLs, TAA-specific CTLs- fixed dose
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Baylor College of Medicine
Hodgkin's Lymphoma, Non-Hodgkin Lymphoma
CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
The subject has a type of lymph gland cancer called Lymphoma. The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancer.
- Trial name
- RELY-30 (NCT02917083)
- Testing
- CAR T Cells
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Baylor College of Medicine
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
Subjects on this study have a type of lymph gland cancer called Non-Hodgkin Lymphoma, acute lymphocytic leukemia, or chronic Lymphocytic Leukemia (these diseases will be referred to as "lymphoma" or "leukemia").
- Conditions
- Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia
- Trial name
- SAGAN (NCT01853631)
- Testing
- Dose Escalation Phase:CD19.CAR/28 and CD19.CAR/28137 T cells, Expansion Phase: CD19.CAR/28 and CD19.CAR/28137 T cells
- Where
- 2 sites in United States
- Volunteers
- 64 people
- Sponsor
- Baylor College of Medicine
Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type, Classical Hodgkin Lymphoma
Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas
This study involved patients that have a cancer called diffuse large B cell lymphoma (DLBCL), NK and T cell lymphomas (NK/TL) or classical Hodgkin lymphoma (cHL) (hereafter these 3 diseases will be referred to as lymphoma).
- Trial name
- NCT04288726
- Testing
- CD30.CAR-EBVST cells
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Baylor College of Medicine
Non-Hodgkin's Lymphoma, B-Cell ALL
Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO)
Patients have a type of lymph gland cancer called Non-Hodgkin Lymphoma (NHL), acute lymphocytic leukemia (ALL) or chronic lymphocytic leukemia (CLL) (these diseases will be referred to as "lymphoma" or "leukemia").
- Conditions
- Non-Hodgkin's Lymphoma, B-Cell ALL, B-Cell CLL
- Trial name
- CARPASCIO (NCT02050347)
- Testing
- CD19.CAR-CD28Z T Cells - dose escalation 2, CD19.CAR-CD28Z T Cells - dose escalation 1
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Baylor College of Medicine
T-cell Acute Lymphoblastic Lymphoma, T-non-Hodgkin Lymphoma
Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells
Patients eligible for this study have a type of blood cancer called T-cell leukemia or lymphoma (lymph gland cancer). The body has different ways of fighting infection and disease.
- Conditions
- T-cell Acute Lymphoblastic Lymphoma, T-non-Hodgkin Lymphoma, T-cell Acute Lymphoblastic Leukemia
- Trial name
- NCT03690011
- Testing
- CD7.CAR/28zeta CAR T cells
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Baylor College of Medicine
CD30-Positive Diffuse Large B-Cell Lymphoma, Anaplastic Large Cell Lymphoma, T Cell and Null Cell Type
Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
This study involves patients with diffuse large B cell lymphoma (DLBCL), natural killer/T-cell lymphoma (NKTL), or classical Hodgkin lymphoma (cHL) (referred to collectively as lymphoma) whose disease has returned or not…
- Conditions
- CD30-Positive Diffuse Large B-Cell Lymphoma, Anaplastic Large Cell Lymphoma, T Cell and Null Cell Type, Anaplastic Large Cell Lymphoma, ALK-Positive, Peripheral T-cell Lymphoma
- Trial name
- CABAL2 (NCT06176690)
- Testing
- C7R.CD30.CAR-EBVST cells
- Where
- 2 sites in United States
- Volunteers
- 90 people
- Sponsor
- Baylor College of Medicine
Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL)
Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT
Subjects are having a bone marrow or SCT for either a type of cancer of the blood called Leukemia or a cancer of the lymph nodes called non- Hodgkin's Lymphoma.
- Conditions
- Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Non Hodgkin's Lymphoma
- Trial name
- MULTIPRAT (NCT00840853)
- Testing
- CD19CAR/virus specific T cells, Benadryl and Tylenol
- Where
- 2 sites in United States
- Volunteers
- 68 people
- Sponsor
- Baylor College of Medicine
B Cell Lymphoma, Chronic Lymphocytic Leukemia
CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL
Patients on this study have a type of lymph gland cancer called non-Hodgkin Lymphoma, Acute Lymphocytic Leukemia, or chronic Lymphocytic Leukemia (these diseases will be referred to as "Lymphoma" or "Leukemia").
- Conditions
- B Cell Lymphoma, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia
- Trial name
- CRETI-NH (NCT00586391)
- Testing
- CD19CAR-28-zeta T cells, Ipilimumab
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Baylor College of Medicine
Human Papillomavirus-Related Carcinoma, Human Papillomavirus Positive Oropharyngeal Carcinoma
HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA
Subjects have a type of cancer that has been associated with an infection with a virus called human papilloma virus (HPV). The cancer has come back, has not gone away after standard treatment or the subject cannot receive…
- Conditions
- Human Papillomavirus-Related Carcinoma, Human Papillomavirus Positive Oropharyngeal Carcinoma, Human Papillomavirus Positive Cervical Carcinoma, Human Papillomavirus Positive Anal Carcinoma
- Trial name
- HESTIA (NCT02379520)
- Testing
- HPV Specific T Cells, Cytoxan, Fludarabine
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Baylor College of Medicine
Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
Administration of Donor T Cells With the Caspase-9 Suicide Gene
Patients will be receiving a stem cell transplant as treatment for their disease. As part of the stem cell transplant, patients will be given very strong doses of chemotherapy, which will kill all their existing stem cells.
- Conditions
- Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelogenous Leukemia
- Trial name
- DOTTI (NCT01494103)
- Testing
- iCaspase9-transduced T cells, AP1903
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Baylor College of Medicine
Endometrial Atypical Hyperplasia, Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia
Semaglutide, Weight Loss, and LNG-IUD for Conservative Treatment of Endometrial Atypical Hyperplasia and Grade 1 Endometrial Cancer
The goal of this clinical trial is to learn if a combination treatment of a hormonal intrauterine device (LNG-IUD), semaglutide, and a structured weight loss program can treat endometrial atypical hyperplasia or grade 1…
- Conditions
- Endometrial Atypical Hyperplasia, Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, Endometrial Cancer Stage I, Endometrial Cancer
- Trial name
- SWIFT (NCT07820358)
- Testing
- Semaglutide (Wegovy) weekly injection, LNG-IUD (Progestin), Structured Weight Loss Program
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- The Methodist Hospital Research Institute
Breast Cancer, Tumor, Breast
TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer
The purpose of this study is to find the biggest dose of HTR2 T cells that is safe, to see how long these cells last in the body, to learn the side effects, and to see if these cells are able to fight and kill HER2 expressing…
- Conditions
- Breast Cancer, Tumor, Breast, Breast Tumor, Malignant Neoplasm of Breast
- Trial name
- NCT06251544
- Testing
- HTR2 T Cells
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Baylor College of Medicine
Alzheimer Dementia (AD)
Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease
Alzheimer's disease (AD) is the most common cause of dementia. Despite major research efforts, effective treatments that slow or stop disease progression remain limited.
- Trial name
- NCT07651319
- Testing
- IL-2 (Aldesleukin), Semaglutide Plus IL-2
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The Methodist Hospital Research Institute
Stroke, Chronic Stroke
Personalized Transcranial Direct Current Stimulation in Stroke Recovery
The central objective of this application is to explore the neural substrate of personalized tDCS (ptDCS) and to determine whether the paradigm for each stroke patient can predict the amount of sustained clinical improvement…
- Conditions
- Stroke, Chronic Stroke, Hemorrhage Brain, Ischemic Stroke
- Trial name
- NCT06286800
- Testing
- Transcranial direct current stimulation (tDCS) with OT
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- The Methodist Hospital Research Institute
Leukemia, Myeloid, Acute, Leukemia, B-cell
Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)
This study is for patients who have a type of blood cancer that expresses the protein CD70, which includes acute myeloid leukemia (AML), T-cell leukemia or B-cell leukemia (and the leukemia has come back or has not gone away…
- Conditions
- Leukemia, Myeloid, Acute, Leukemia, B-cell, Leukemia, T-Cell
- Trial name
- CASEY (NCT06345027)
- Testing
- Treatment Arm A
- Where
- 2 sites in United States
- Volunteers
- 78 people
- Sponsor
- Baylor College of Medicine
Lymphoma, Myeloma
CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors
This study is for patients who have a type of cancer that expresses the protein CD70, which includes lymphoma (lymph gland cancer), myeloma and solid tumors including some sarcomas and kidney cancers, and the cancer has come back…
- Conditions
- Lymphoma, Myeloma, Solid Tumors, Sarcoma
- Trial name
- CALySSEY (NCT07297160)
- Testing
- Dose Level -1, Dose Level 1 (starting dose level), Dose Level 2
- Where
- 2 sites in United States
- Sponsor
- Baylor College of Medicine